"The U.S. Food and Drug Administration will complete its phase-out of all inhaler medical products containing chlorofluorocarbons (CFCs) by Dec. 31, 2013. This effort is to comply with an international treaty to protect the ozone layer by phasing "...
Qvar Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Qvar (beclomethasone dipropionate) is used to prevent asthma attacks. It will not treat an asthma attack that has already begun. Qvar is a steroid. This medication is available in generic form. Common side effects include stomach upset, nausea, vomiting, headache, sore throat, stuffy nose, or unpleasant taste in the mouth.
The recommended dose of Qvar is 40 to 320 mcg twice daily for adults and 40 to 80 mg twice daily for children. If you are also using a bronchodilator, use it first before using the beclomethasone inhaler. There may be other drugs that can interact with Qvar. Tell your doctor about all the prescription and over-the-counter medications you use. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Qvar should be used only when prescribed during pregnancy. There are rare reports of harm to a fetus when the mother took other corticosteroids. Infants born to mothers who have been using high doses of beclomethasone for an extended time may have hormone problems. Tell your doctor if you notice symptoms such as persistent nausea/vomiting, severe diarrhea, or weakness in your newborn. It is not known if this medication passes into breast milk. Consult your doctor before breast-feeding.
Our Qvar (beclomethasone dipropionate) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
What is Patient Information in Detail?
Easy-to-read and understand detailed drug information and pill images for the patient or caregiver from Cerner Multum.
Qvar in Detail - Patient Information: Side Effects
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have:
- weakness, tired feeling, nausea, loss of appetite, weight loss;
- white patches or sores inside your mouth or on your lips;
- wheezing, choking, or other breathing problems after using this medication;
- skin rash, bruising, severe tingling, numbness, pain, muscle weakness;
- changes in the shape or location of body fat (especially in your arms, legs, face, neck, breasts, and waist);
- blurred vision, eye pain, or seeing halos around lights; or
- worsening asthma symptoms.
Common side effects may include:
- dryness in your mouth, nose, or throat after use;
- stuffy nose, sinus pain, sore throat, cough; or
- hoarseness or deepened voice.
Read the entire detailed patient monograph for Qvar (Beclomethasone Dipropionate HFA) »
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Qvar FDA Prescribing Information: Side Effects
The following reporting rates of common adverse experiences are based upon 4 clinical trials in which 1196 Patients (671 female and 525 male adults previously treated with as-needed bronchodilators and/or inhaled corticosteroids) were treated with QVAR (doses of 40, 80, 160, or 320 mcg twice daily) or CFC-BDP (doses of 42, 168, or 336 mcg twice daily) or placebo. The table below includes all events reported by patients taking QVAR (whether considered drug related or not) that occurred at a rate over 3% for either QVAR or CFC-BDP. In considering these data, difference in average duration of exposure and clinical trial design should be taken into account.
Adverse Events Reported by at Least 3% of the Patients
for Either QVAR or CFC-BDP by Treatment and Daily Dose
|UPPER RESP TRACT INFECTION||11||9||7||11||5||12||3||9||17|
|INCREASED ASTHMA SYMPTOMS||18||3||2||4||0||8||14||5||7|
|ORAL SYMPTOMS INHALATION ROUTE||2||3||3||3||2||6||7||5||5|
|BACK PAIN||1||1||2||< 1||4||4||2||4||4|
Other adverse events that occurred in these clinical trials using QVAR with an incidence of 1% to 3% and which occurred at a greater incidence than placebo were: dysphonia, dysmenorrhea and coughing.
No patients treated with QVAR in the clinical development program developed symptomatic oropharyngeal candidiasis. If such an infection develops, treatment with appropriate antifungal therapy or discontinuance of treatment with QVAR may be required.
In two 12-week placebo-controlled studies in steroid naive pediatric patients 5 to 12 years of age, no clinically relevant differences were found in the pattern, severity, or frequency of adverse events compared with those reported in adults, with the exception of conditions which are more prevalent in a pediatric population generally.
Adverse Event Reports from Other Sources
Rare cases of immediate and delayed hypersensitivity reactions, including urticaria, angioedema, rash, and bronchospasm, have been reported following the oral and intranasal inhalation of beclomethasone dipropionate.
During postmarketing experience, psychiatric events and behavioral changes such as aggression, depression, sleep disorders, psychomotor hyperactivity, and suicidal ideation have been reported (primarily in children). Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Read the entire FDA prescribing information for Qvar (Beclomethasone Dipropionate HFA) »
Additional Qvar Information
Report Problems to the Food and Drug Administration
Allergies & Asthma
Improve treatments & prevent attacks.